Table 3. Relationship between DNA promoter methylation status and prognosis.
| T value | AUC | D/n | p/y | HR | IC95 | p-value | |||
|---|---|---|---|---|---|---|---|---|---|
| A. Early stages of PDAC (stage IA, IB and IIA) | |||||||||
| 1. MUC1 | neoplastic region | Hyper | < 46.87 | 0.691 | 3/11 | 0.53 | 1.00 | ref | |
| Hypo | 13/21 | 1.48 | 1.13 | 0.32-4.05 | 0.850 | ||||
| non-neoplastic region | Hyper | < 64.10 | 0.605 | 6/30 | 1.48 | 1.00 | ref | ||
| Hypo | 13/34 | 1.85 | 1.73 | 0.66-4.57 | 0.260 | ||||
| 2. MUC4 | neoplastic region | Hyper | < 82.20 | 0.777 | 6/21 | 1.29 | 1.00 | ref | |
| Hypo | 10/11 | 0.72 | 2.60 | 0.94-7.19 | 0.048 | ||||
| non-neoplastic region | Hyper | < 70.57 | 0.768 | 4/39 | 1.78 | 1.00 | ref | ||
| Hypo | 15/25 | 1.54 | 4.78 | 1.57-14.49 | 0.002 | ||||
| 3. MUC1/MUC4 | neoplastic region | other | 7/22 | 1.33 | 1.00 | ref | |||
| Both Hypo | 9/10 | 0.68 | 2.12 | 0.78- 5.72 | 0.130 | ||||
| non-neoplastic region | other | 8/48 | 2.44 | 1.00 | ref | ||||
| Both Hypo | 11/16 | 0.88 | 4.21 | 1.69-10.49 | <0.001 | ||||
| B. Advanced stages of PDAC (stage IIB, III and IV) | |||||||||
| 1. MUC1 | neoplastic region | Hyper | < 61.39 | 0.627 | 17/39 | 2.43 | 1.00 | ref | |
| Hypo | 9/11 | 0.34 | 3.36 | 1.44- 7.89 | 0.003 | ||||
| non-neoplastic region | Hyper | < 35.63 | 0.586 | 1/10 | 0.29 | 1.00 | ref | ||
| Hypo | 29/59 | 3.28 | 3.06 | 0.41-22.74 | 0.250 | ||||
| 2. MUC4 | neoplastic region | Hyper | < 75.58 | 0.704 | 10/29 | 1.59 | 1.00 | ref | |
| Hypo | 16/21 | 1.19 | 2.47 | 1.10-5.56 | 0.024 | ||||
| non-neoplastic region | Hyper | < 72.00 | 0.683 | 12/41 | 1.74 | 1.00 | ref | ||
| Hypo | 18/28 | 1.82 | 1.48 | 0.69- 3.15 | 0.309 | ||||
| 3. MUC1/MUC4 | neoplastic region | Both Hyper | 9/28 | 1.58 | 1.00 | ref | |||
| other | 17/22 | 1.19 | 2.90 | 1.23- 6.63 | 0.008 | ||||
| non-neoplastic region | Both Hyper | 4/8 | 0.38 | 1.00 | ref | ||||
| other | 22/61 | 2.39 | 1.01 | 0.35-3.00 | 0.149 | ||||
| C. Stage IIA and IIB | |||||||||
| 1. MUC1 | neoplastic region | Hyper | < 62.17 | 0.659 | 22/50 | 3.07 | 1.00 | ref | |
| Hypo | 14/17 | 0.73 | 2.65 | 1.32-5.44 | 0.005 | ||||
| non-neoplastic region | Hyper | < 64.78 | 0.634 | 21/58 | 2.40 | 1.00 | ref | ||
| Hypo | 22/38 | 2.45 | 1.04 | 0.61-1.87 | 0.922 | ||||
| 2. MUC4 | neoplastic region | Hyper | < 82.75 | 0.763 | 15/44 | 2.57 | 1.00 | ref | |
| Hypo | 21/23 | 1.22 | 3.02 | 1.54-5.39 | <0.001 | ||||
| non-neoplastic region | Hyper | < 72.00 | 0.703 | 15/55 | 2.18 | 1.00 | ref | ||
| Hypo | 28/41 | 2.67 | 1.41 | 0.74-2.71 | 0.297 | ||||
| 3. MUC1/MUC4 | neoplastic region | Both Hyper | 10/37 | 2.21 | 1.00 | ref | |||
| other | 26/30 | 1.59 | 3.59 | 1.71-7.54 | <0.001 | ||||
| non-neoplastic region | Both Hyper | 16/48 | 1.85 | 1.00 | ref | ||||
| other | 27/45 | 3.01 | 1.04 | 0.55-1.96 | 0.895 | ||||
T value: Threshold value, AUC: Area under the curve, D/n: Death/number, p/y: person-years, HR: hazard ratio, Hyper: Hypermethylation, Hypo: Hypomethylation.